Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2000
06/02/2000WO2000031242A2 Engineered cytotoxic ribonuclease
06/02/2000WO2000031238A2 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
06/02/2000WO2000031235A2 Nucleotide and protein sequences of nogo genes and methods based thereon
06/02/2000WO2000031140A1 Inhibitor of metalocarboxypeptidases as fibrinolytic agent
06/02/2000WO2000031139A1 Peptide inhibitor of browman-birk type
06/02/2000WO2000031138A1 Membrane antigenic structure inducing stoppage of proliferation and apoptosis of activated t-lymphocytes
06/02/2000WO2000031137A1 Amino-terminal modified parathyroid hormone (pth) analogs
06/02/2000WO2000031136A1 Antagonistic analogs of gh-rh inhibiting igf-i and -ii
06/02/2000WO2000031135A1 TGF$G(b)1 INHIBITOR PEPTIDES
06/02/2000WO2000031133A2 Potassium channel interactors and uses therefor
06/02/2000WO2000031132A1 Novel polypeptide
06/02/2000WO2000031131A1 Peptide fragments having cell death inhibitory activity
06/02/2000WO2000031129A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
06/02/2000WO2000031128A1 Chimeric biotin-binding papillomavirus protein
06/02/2000WO2000031124A2 Peptides that modulate the interaction of b class ephrins and pdz domains
06/02/2000WO2000031123A2 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
06/02/2000WO2000031122A1 Hydrophilic somatostatin analogs
06/02/2000WO2000031120A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000WO2000031115A1 Methods of identifying antigen gene sequences
06/02/2000WO2000031113A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN
06/02/2000WO2000031111A1 Antisense modulation of nf-kappa-b p65 subunit expression
06/02/2000WO2000031110A1 Identification of disease predictive nucleic acids
06/02/2000WO2000031106A1 Antisense modulation of mek1 expression
06/02/2000WO2000031105A1 Antisense modulation of inhibitor-kappa b kinase-beta expression
06/02/2000WO2000031103A1 Antisense modulation of mek2 expression
06/02/2000WO2000031083A1 Phospholipid derivatives of non-steroidal anti-inflammatory drugs
06/02/2000WO2000030686A1 Antisense modulation of inhibitor-kappa b kinase-alpha expression
06/02/2000WO2000030681A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000WO2000030680A1 Tumor antigen-specific antibody-gp39 chimeric protein constructs
06/02/2000WO2000030677A1 Method of treating viral hemorrhagic fever
06/02/2000WO2000030676A1 Method of treating sickle cell disease and thalassemia
06/02/2000WO2000030675A2 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
06/02/2000WO2000030674A1 Neuropeptide y y4 agents in the treatment of reproductive disorders
06/02/2000WO2000030673A1 Uses for eph receptor antagonists and agonists to treat vascular disorders
06/02/2000WO2000030672A1 Collagen based biomaterials and methods of preparation and use
06/02/2000WO2000030671A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000WO2000030670A1 Effects of gdnf and ngf on sodium channels in drg neurons
06/02/2000WO2000030669A2 Use of plasma phospholipid transfer proteins in treating cardiovascular dieases
06/02/2000WO2000030668A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
06/02/2000WO2000030667A2 Compositions and methods using lactadherin or variants thereof
06/02/2000WO2000030665A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000WO2000030664A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
06/02/2000WO2000030663A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases
06/02/2000WO2000030656A1 Neuron stimulation by ribavirin, and analogs thereof
06/02/2000WO2000030635A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000WO2000030618A1 Particles based on polyamino-acid(s) and methods for preparing same
06/02/2000WO2000030616A1 Dispersible phospholipid stabilized microparticles
06/02/2000WO2000030614A1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
06/02/2000WO2000030613A1 New process
06/02/2000WO2000030590A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
06/02/2000WO2000030588A2 Treatment of hypertension
06/02/2000WO2000030587A2 NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES
06/02/2000WO2000030578A1 Enzymatic treatment and prevention of hypertrophic skin
06/02/2000WO2000030436A1 Stabilisation of milk from transgenic animals
06/02/2000WO2000030425A2 Method of using pon-1 to decrease atheroma formation
06/02/2000WO2000015774A9 Useful properties of a bee venom protein and gene encoding same
06/02/2000WO2000014244A3 Treatment of cervical cancer
06/02/2000WO2000014236A3 Grf analogs with increased biological potency
06/02/2000WO2000013710A3 Hydrogel compositions for the controlled release administration of growth factors
06/02/2000WO2000013703A9 Methods of treating hypertension and compositions for use therein
06/02/2000WO2000013650A3 Neuroprotection
06/02/2000WO2000012545A3 Antibodies specific for bladder nuclear matrix proteins blca-1 to blca-6
06/02/2000WO2000012119A3 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa
06/02/2000WO2000011141A3 Trna binding domain
06/02/2000WO2000011030A3 Method for chromatographically purifying insulins
06/02/2000WO2000009526A3 Method for dpc4 (smad4) nuclear localization
06/02/2000WO2000008213A9 Oligomers which inhibit expression of collagen genes
06/02/2000WO2000008045A3 Novel molecules of the tango-93-related protein family and uses thereof
06/02/2000WO2000007610A8 Interacting proteins for autoantigens of autoimmune diseases
06/02/2000WO2000006203A9 Dna cytokine vaccines and use of same for protective immunity against multiple sclerosis
06/02/2000WO1999064594A8 Genes and gene expression products that are differentially regulated in prostate cancer
06/02/2000WO1999062942A3 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
06/02/2000WO1999054446A3 Human nucleic acid sequences which are overexpressed in normal pancreas tissue
06/02/2000CA2364669A1 Testis-specific cystatin-like protein cystatin t
06/02/2000CA2352963A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000CA2352606A1 Urotensins ii of mammals and their uses
06/02/2000CA2352600A1 Inhibitor of metalocarboxypeptidases as fibrinolytic agent
06/02/2000CA2352599A1 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000CA2352585A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000CA2352510A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases
06/02/2000CA2352495A1 Human semaphorin 6a-1 (sema6a-a), a gene involved in neuronal development and regeneration mechanisms during apoptosis, and its use as a potential drug target
06/02/2000CA2352493A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
06/02/2000CA2352486A1 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
06/02/2000CA2352477A1 Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof
06/02/2000CA2352458A1 Compositions and methods using lactadherin or variants thereof
06/02/2000CA2352347A1 Novel polypeptide
06/02/2000CA2352338A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
06/02/2000CA2352316A1 Treatment of hypertension
06/02/2000CA2352043A1 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
06/02/2000CA2351944A1 Hydrophilic somatostatin analogs
06/02/2000CA2351943A1 Stabilisation of milk from transgenic animals
06/02/2000CA2351893A1 Peptides that modulate the interaction of b class ephrins and pdz domains
06/02/2000CA2351737A1 Efficient methods for producing antimicrobial cationic peptides in host cells
06/02/2000CA2351736A1 Methods of identifying antigen gene sequences
06/02/2000CA2351733A1 Nf-kb activation inhibitors, and their pharmaceutical uses
06/02/2000CA2351614A1 Chimeric biotin-binding papillomavirus protein
06/02/2000CA2351591A1 Method of treating sickle cell disease and thalassemia
06/02/2000CA2351470A1 Method of treating viral hemorrhagic fever
06/02/2000CA2351365A1 Potassium channel interactors and uses therefor
06/02/2000CA2351361A1 Gtpase associated proteins
1 ... 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 ... 3163